Search results for "Highlights"


 
Results 81 - 90 of about 440 for "Highlights".
Sort by: Relevance | Newest | Oldest

Statins compared for non-HDL cholesterol levels in patients with diabetes

Moderate- and high-intensity rosuvastatin and high-intensity simvastatin and atorvastatin were most effective at moderately reducing levels of non-high-density lipoprotein (HDL) cholesterol, a systematic review and meta-analysis found.
https://diabetes.acponline.org/archives/2022/04/08/1.htm
8 Apr 2022

Recent articles address federal diabetes programs, type 1 diabetes care

The National Clinical Care Commission made 39 recommendations for improving federal diabetes programs, and the latest In the Clinic article offered advice on diagnosing and treating type 1 diabetes.
https://diabetes.acponline.org/archives/2022/03/11/6.htm
11 Mar 2022

Interventions uncommon for prediabetes in primary care

A U.S. retrospective study found that while 63.4% of prediabetes patients had repeated glycemic testing over one year of follow-up, 10.4% had a primary care visit with a coded diagnosis of prediabetes, 1.0% were referred for nutrition services, and 5.4% were prescribed metformin.
https://diabetes.acponline.org/archives/2022/03/11/2.htm
11 Mar 2022

Severe insulin-resistant diabetes associated with better metabolic surgery outcomes

Patients with severe insulin-resistant diabetes had better outcomes after metabolic surgery than those with mild obesity-related diabetes or severe insulin-deficient diabetes, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk.
https://diabetes.acponline.org/archives/2022/03/11/3.htm
11 Mar 2022

SGLT-2 inhibitors linked to more diabetic ketoacidosis vs. DPP-4 inhibitors or sulfonylureas

A retrospective study found that new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors developed diabetic ketoacidosis at a rate of about 6 per 1,000 person-years, compared to 4.3 or 4.5 per 1,000 person-years with dipeptidyl peptidase-4 (DPP-4) inhibitors or sulfonylureas, respectively.
https://diabetes.acponline.org/archives/2022/03/11/1.htm
11 Mar 2022

Obesity increasing in type 1 diabetes, associated with higher risk for chronic kidney disease

Obesity in type 1 diabetes rose from 2004 to 2018, and patients with type 1 had a higher adjusted prevalence of low estimated glomerular filtration rate and albuminuria than those with type 2, an analysis of one health system found.
https://diabetes.acponline.org/archives/2022/02/11/3.htm
11 Feb 2022

Nearly one-third of patients were nonadherent to newly prescribed SGLT-2 inhibitors, GLP-1 receptor agonists

Factors associated with not filling a new prescription for a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist included older age, Black race, male sex, certain comorbid conditions, and having a primary care clinician prescribe the drug, a study found.
https://diabetes.acponline.org/archives/2022/02/11/2.htm
11 Feb 2022

Tirzepatide may improve glycemic control when added to insulin glargine in type 2 diabetes

An industry-sponsored phase 3 trial found statistically significant improvements in HbA1c level among patients with type 2 diabetes who had inadequate glycemic control on insulin glargine and were randomly assigned to subcutaneous tirzepatide once weekly versus placebo.
https://diabetes.acponline.org/archives/2022/02/11/1.htm
11 Feb 2022

Metformin use during pregnancy not associated with adverse outcomes in children

A industry-conducted cohort study in Finland found that childhood obesity, hypoglycemia, hyperglycemia, diabetes, and challenges in motor-social development did not appear to be associated with in utero exposure to metformin or metformin and insulin versus insulin alone.
https://diabetes.acponline.org/archives/2022/01/14/3.htm
14 Jan 2022

Association of inflammation with mortality in COVID-19 didn't differ by diabetes status

A single-center, case-control study of patients who were hospitalized with COVID-19 found a link between elevated levels of IL-6, IL-8, and interferon-γ-induced protein 10 and mortality risk, regardless of whether patients had type 2 diabetes.
https://diabetes.acponline.org/archives/2022/01/14/2.htm
14 Jan 2022

Result Page: Prev   4   5   6   7   8   9   10   11   12   13   Next